Anthropic has established a physical biology laboratory in the San Francisco Bay Area as it advances its artificial-intelligence-driven drug discovery program. The move signifies the startup's commitment to moving beyond computer-based evaluations and into practical experimentation to address diseases the pharmaceutical industry may be overlooking.
Eric Kauderer-Abrams, Anthropic’s head of life sciences, confirmed the existence of the wet lab, stating that real-world laboratory work remains the ultimate test for biological research. He described their approach as similar to that of typical biotech companies, involving both in-house experiments and collaborations with external partners. A spokesperson clarified that the lab is not exclusively for drug discovery but supports broader life sciences work.
This initiative aligns with Anthropic’s larger goal of developing powerful AI for global benefit, with life sciences identified as a key area of opportunity. The company aims to tackle conditions considered “undruggable” by traditional methods, potentially accelerating the discovery of complex molecules like bispecific and trispecific antibodies.
Anthropic is also exploring the automation of laboratory tasks, with ambitions for its Claude AI to direct robotic units for scientific experiments, albeit with a continued emphasis on human oversight for safety. Kauderer-Abrams noted that this integration of AI into lab work is in its early stages but holds the potential for significant acceleration across various processes.
The expansion into physical biology occurs amid broader discussions within Anthropic and the AI community regarding the potential risks and existential threats posed by advanced AI. CEO Dario Amodei has previously called for a development slowdown, citing concerns about catastrophic damage from future AI systems, while the company also prepares for a significant public offering.
Kauderer-Abrams acknowledged the dual nature of their work, stating, “In our life-science work, we’re always balancing these things – making models better in ways that we think will uplift and accelerate developing medicines, and being thoughtful and careful about how we deploy it to limit the risk.”
Anthropic publicly stated its intention to pursue drug programs at a June event, highlighting a focus on preclinical work in areas not financially attractive to established companies. The company has also launched software like Claude Science and acquired Coefficient Bio to enhance its drug development tools. Hiring efforts indicate a ramp-up in procurement and specialized biochemical expertise.
While Anthropic aims to speed up progress in life sciences, the timeline for bringing any potential drug to market remains long, with clinical trials typically taking years. Rival Alphabet's Isomorphic Labs has also faced delays in advancing its drug discovery goals to the clinic.
Anthropic is also working to build trust with pharmaceutical partners, such as Roche’s Genentech, Bristol Myers Squibb, and Novo Nordisk, who use Anthropic's AI services and tools. The company emphasizes that it is not currently conducting clinical trials, focusing instead on areas where the industry has unmet needs and not competing directly with companies whose business model is bringing drugs to market.